IPO Year: 2023
Exchange: NASDAQ
Date | Price Target | Rating | Analyst |
---|---|---|---|
8/28/2024 | $10.00 | Buy | ROTH MKM |
11/27/2023 | $35.00 | Buy | H.C. Wainwright |
9/12/2023 | $40.00 | Buy | Maxim Group |
2/15/2023 | $10.00 | Speculative Buy | The Benchmark Company |
SC 13G - GENELUX Corp (0001231457) (Subject)
SC 13G - GENELUX Corp (0001231457) (Subject)
4 - GENELUX Corp (0001231457) (Issuer)
4 - GENELUX Corp (0001231457) (Issuer)
4 - GENELUX Corp (0001231457) (Issuer)
4 - GENELUX Corp (0001231457) (Issuer)
4 - GENELUX Corp (0001231457) (Issuer)
4 - GENELUX Corp (0001231457) (Issuer)
4 - GENELUX Corp (0001231457) (Issuer)
4 - GENELUX Corp (0001231457) (Issuer)
4 - GENELUX Corp (0001231457) (Issuer)
ROTH MKM initiated coverage of Genelux with a rating of Buy and set a new price target of $10.00
H.C. Wainwright initiated coverage of Genelux with a rating of Buy and set a new price target of $35.00
Maxim Group initiated coverage of Genelux with a rating of Buy and set a new price target of $40.00
The Benchmark Company initiated coverage of Genelux with a rating of Speculative Buy and set a new price target of $10.00
8-K - GENELUX Corp (0001231457) (Filer)
10-Q - GENELUX Corp (0001231457) (Filer)
8-K - GENELUX Corp (0001231457) (Filer)
8-K - GENELUX Corp (0001231457) (Filer)
ARS - GENELUX Corp (0001231457) (Filer)
DEFA14A - GENELUX Corp (0001231457) (Filer)
DEF 14A - GENELUX Corp (0001231457) (Filer)
8-K - GENELUX Corp (0001231457) (Filer)
424B5 - GENELUX Corp (0001231457) (Filer)
8-K - GENELUX Corp (0001231457) (Filer)
Recently, on June 7, 2024, Michael L Berger, a significant figure at Air Transport Services Group Inc, made a notable insider purchase. Berger bought $49,830 worth of shares, acquiring 3,996 units at a price of $12.47 per share. This transaction increased his direct ownership by 4% to 103,705 units as reported in the SEC Form 4 here. Examining other insider actions within the company can sometimes reveal intriguing patterns that might offer insights for investors. Looking back at previous transactions, we see a series of insider activities at Air Transport Services Group Inc: In March 2024, Dominick Jeffrey A. filed an SEC Form 4, indicating a notable transaction date in which actions were
WESTLAKE VILLAGE, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ:GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, Chairman and CEO, will discuss clinical-stage programs, recent announcements, and upcoming milestones in a fireside chat at the H.C. Wainwright Global Healthcare Conference, taking place September 9-11, 2024, in New York City, New York. The conversation with Emily Bodnar, Vice President, Equity Research and H.C. Wainwright Biotechnology Analyst, is scheduled to begin at 12:30 p.m. ET on Wednesday, September 11, 2024. A webcast link for the H.C. Wainwright Conference event will be available at https:/
WESTLAKE VILLAGE, Calif., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ:GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the second quarter of 2024 and provided general business updates. "The past quarter has continued to be transformative for the company as we completed a key financing expected to provide runway through three trial readouts, including our ongoing Phase 3 trial in platinum resistant/refractory ovarian cancer," said Thomas Zindrick, President, Chairman and CEO of Genelux. "Beyond our pivotal Phase 3 trial, we look to provide interim data for systemic delivery of Olvi-Vec in both small and non-small cell lung canc
WESTLAKE VILLAGE, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ:GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, CEO and Chairman, will discuss clinical-stage programs, recent announcements, and upcoming milestones in a fireside chat at BTIG's Virtual Biotechnology Conference 2024. The conversation with Kaveri Pohlman, PhD, Director and BTIG Biotechnology Analyst, is scheduled to begin at 12:00 p.m. ET on Tuesday, August 6, 2024. About Genelux CorporationGenelux is a late clinical-stage biopharmaceutical company focused on developing a pipeline of next-generation oncolytic immunotherapies for patients suffering
WESTLAKE VILLAGE, Calif., May 24, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (Genelux) (NASDAQ:GNLX), a late clinical-stage immuno-oncology company, today announced the pricing of an underwritten offering of 6,875,000 shares of its common stock and accompanying warrants to purchase 6,875,000 shares of its common stock at a combined offering price of $4.00 per share and accompanying warrant, in each case before underwriting discounts and commissions. Each warrant will have an exercise price of $5.25 per share, will be immediately exercisable following the closing of the offering and will expire five years from the date of issuance. Gross proceeds to Genelux from the offering are expected
WESTLAKE VILLAGE, Calif., May 23, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (Genelux) (NASDAQ:GNLX), a late clinical-stage immuno-oncology company, today announced that it has commenced an underwritten public offering of its common stock and accompanying warrants. All shares of common stock and accompanying warrants are being offered by Genelux. In addition, Genelux expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares of common stock sold in connection with the offering (including shares underlying the warrants). Guggenheim Securities is acting as sole book-running manager for the offering. Newbridge Securities Corporation is act
WESTLAKE VILLAGE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ:GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the first quarter of 2024 and provided general business updates. "Our pivotal Phase 3 registration trial of Olvi-Vec in platinum resistant/refractory ovarian cancer continues to enroll patients," said Thomas Zindrick, President, Chairman and CEO of Genelux. "Looking ahead, we are excited about advancing Olvi-Vec into additional cancer indications through intravenous administration, a physician-preferred route of delivery, and seeking to further validate our hypothesis that Olvi-Vec may reverse resistance to pla
– Continued active enrollment of Olvi-Vec in our pivotal Phase 3 OnPrime/GOG-3076 trial in platinum resistant/refractory ovarian cancer with topline results anticipated in 2H 2025 – – Initiation of Phase 2 trial in non-small cell lung cancer (recurrent/platinum-ICI failure) with systemic administration of Olvi-Vec expected in 1H 2024 – – Ongoing Phase 1b/2 trial with systemic administration of Olvi-Vec in small cell lung cancer expected interim readout in 2H 2024 – – $23.2 million in cash, cash equivalents and short-term investments – WESTLAKE VILLAGE, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ:GNLX), a late clinical-stage immuno-oncology company, re
- Pivotal Phase 3 Study of Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer Initiated in September 2022 - - Phase 2 Trial of Olvi-Vec- Demonstrated Clinical Reversal of Platinum Resistance and Refractoriness and Met Primary Endpoint of Objective Response Rate with Durable Responses - WESTLAKE VILLAGE, Calif., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ:GNLX), a late clinical-stage immuno-oncology company, today announced that the United States Food and Drug Administration (FDA) has granted Fast Track designation for the development program of Olvi-Vec (olvimulogene nanivacirepvec) for the treatment of patients with platinum resistant/refractory ovarian cancer.
- Expanded executive team as Lourie Zak appointed Chief Financial Officer - - Extended clinical focus on systemic administration in small cell lung cancer - - $29.9 million in cash and equivalents - WESTLAKE VILLAGE, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ:GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the third quarter of 2023 and provided general business updates. "The third quarter was highlighted by continued expansion of our executive team while advancing our pivotal Phase 3 study in platinum resistant/refractory ovarian cancer. Additionally, our small cell lung cancer trial is progressing," said Thomas Z
WESTLAKE VILLAGE, Calif., Sept. 14, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ:GNLX), a late clinical-stage immuno-oncology company, today announced that on September 11, 2023, the Company's Board of Directors (the "Board") granted inducement awards consisting of non-qualified stock options to purchase 444,300 shares of common stock to seven new employees under the Company's 2023 Inducement Plan, including an option to purchase 150,000 shares of common stock to Lourie Zak, the Company's new Chief Financial Officer, an option to purchase 88,000 shares of common stock to Caroline Jewett, the Company's new Head of Quality, and an option to purchase 54,000 shares of common stock to R
4/A - GENELUX Corp (0001231457) (Issuer)
4 - GENELUX Corp (0001231457) (Issuer)
4 - GENELUX Corp (0001231457) (Issuer)
4 - GENELUX Corp (0001231457) (Issuer)
4 - GENELUX Corp (0001231457) (Issuer)
4 - GENELUX Corp (0001231457) (Issuer)
4 - GENELUX Corp (0001231457) (Issuer)
4 - GENELUX Corp (0001231457) (Issuer)
4 - GENELUX Corp (0001231457) (Issuer)
4 - GENELUX Corp (0001231457) (Issuer)
Recently, on June 7, 2024, Michael L Berger, a significant figure at Air Transport Services Group Inc, made a notable insider purchase. Berger bought $49,830 worth of shares, acquiring 3,996 units at a price of $12.47 per share. This transaction increased his direct ownership by 4% to 103,705 units as reported in the SEC Form 4 here. Examining other insider actions within the company can sometimes reveal intriguing patterns that might offer insights for investors. Looking back at previous transactions, we see a series of insider activities at Air Transport Services Group Inc: In March 2024, Dominick Jeffrey A. filed an SEC Form 4, indicating a notable transaction date in which actions were
Benchmark analyst Bruce Jackson reiterates Genelux (NASDAQ:GNLX) with a Speculative Buy and maintains $25 price target.
Genelux (NASDAQ:GNLX) underwent analysis by 4 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 2 0 0 0 Last 30D 0 1 0 0 0 1M Ago 1 0 0 0 0 2M Ago 1 1 0 0 0 3M Ago 0 0 0 0 0 The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $29.75, a high estimate of $32.00, and a low estimate of $25.00. This current average represents a 8.46% decrease from the previous
Benchmark analyst Bruce Jackson maintains Genelux (NASDAQ:GNLX) with a Speculative Buy and lowers the price target from $30 to $25.
Gainers Innovative Eyewear (NASDAQ:LUCY) shares moved upwards by 421.5% to $0.97 during Monday's regular session. The company's market cap stands at $16.9 million. OneMedNet (NASDAQ:ONMD) shares moved upwards by 55.78% to $2.29. The company's market cap stands at $54.6 million. Qilian Intl Hldg Gr (NASDAQ:QLI) shares moved upwards by 37.59% to $0.91. The company's market cap stands at $32.4 million. Onconetix (NASDAQ:ONCO) shares moved upwards by 29.7% to $0.18. The market value of their outstanding shares is at $4.0 million. TransCode Therapeutics (NASDAQ:RNAZ) shares moved upwards by 28.77% to $1.79. The company's market cap stands at $11.8 million. MultiPlan (NYSE:MPLN) stock rose 2
Gainers Cue Health (NASDAQ:HLTH) stock moved upwards by 32.4% to $0.12 during Monday's pre-market session. The market value of their outstanding shares is at $19.8 million. SCWorx (NASDAQ:WORX) shares increased by 25.53% to $2.36. The company's market cap stands at $2.8 million. Innovative Eyewear (NASDAQ:LUCY) stock rose 19.62% to $0.22. The company's market cap stands at $3.8 million. Vaccinex (NASDAQ:VCNX) stock rose 17.86% to $6.07. The market value of their outstanding shares is at $9.6 million. Guardant Health (NASDAQ:GH) shares increased by 15.35% to $26.3. The company's market cap stands at $3.2 billion. Scinai Immunotherapeutics (NASDAQ:SCNI) stock rose 14.63% to $4.22. The co
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining more than 1% on Friday. The Dow traded up 0.12% to 39,112.74 while the NASDAQ rose 1.08% to 16,917.09. The S&P 500 also rose, gaining, 0.70% to 5,304.78. Check This Out: Top 3 Health Care Stocks That May Crash In May Leading and Lagging SectorsCommunication services shares jumped by 1.3% on Friday. In trading on Friday, health care shares fell by 0.1%. Top Headline The total number of active U.S. oil rigs came in unchanged at 497 rigs this week, Baker Hughes Inc reported. Equities Trading UP Akanda Corp. (NASDAQ:AKAN) shares shot up 34% to $3.2001. The inter
Shares of NetEase, Inc. (NASDAQ:NTES) fell during Friday's session after the company reported worse-than-expected first-quarter revenue. NetEase reported fiscal first-quarter 2024 revenue growth of 7.2% year-on-year to $3.72 billion (26.9 billion Chinese yuan), missing the analyst consensus estimate of $3.79 billion. The Chinese gaming player’s adjusted EPADS of $1.81 beat the analyst consensus estimate of $1.79, according to data from Benzinga Pro. NetEase shares declined 4% to $91.02 on Friday. Here are some other stocks moving in today’s mid-day session. Gainers Akanda Corp. (NASDAQ:AKAN) shares climbed 101% to $4.81. The international medical cannabis company implemented
Gainers Innovative Eyewear (NASDAQ:LUCY) shares increased by 328.8% to $0.8 during Friday's regular session. The market value of their outstanding shares is at $13.9 million. OneMedNet (NASDAQ:ONMD) shares increased by 66.66% to $2.45. The market value of their outstanding shares is at $58.4 million. TransCode Therapeutics (NASDAQ:RNAZ) stock rose 28.05% to $1.78. The company's market cap stands at $11.7 million. Onconetix (NASDAQ:ONCO) shares moved upwards by 20.15% to $0.17. The market value of their outstanding shares is at $3.7 million. The company's, Q1 earnings came out 4 days ago. Aptorum Gr (NASDAQ:APM) shares moved upwards by 17.2% to $4.7. The market value of their outstanding